The UK and US have concluded a key commercial pact that will keep zero levies on UK medicine products going into the American market.
The Terms of the Pact
In exchange for the tariff guarantee, the UK has committed to raise funding on pharmaceuticals through the National Health Service (NHS). This move ensures that import taxes on these crucial exports will remain at zero for a timeframe of 36 months.
This development follows previous threats to significantly raise tariffs on branded drug imports, with figures floated as high as double the cost.
"This deal with the UK strengthens the worldwide climate for cutting-edge drugs and brings much-needed balance to transatlantic pharmaceutical trade," an announcement said.
Commercial Importance
Pharmaceuticals represent one of the Britain's biggest goods shipped to the United States, which is clearly the largest destination for leading companies like GSK and AstraZeneca.
Export figures indicate that in the year to the end of the third quarter, the UK shipped medicines worth over eleven billion pounds to the US. This value made up nearly one-fifth of all goods exports in that period.
"This deal protects jobs, boosts capital expenditure and sets the stage for the UK to establish itself as a global hub for life sciences," a minister remarked.
Detailed British Pledges
The pact entails several notable pledges from the British government:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new medicines to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to raise overall public funding on medicines from 0.3% of GDP to 0.6% over the following ten-year period.
- Payback Limit: The percentage drug companies must refund to the NHS to stay within budget will be capped at fifteen percent. Previously, repayments were more than 20%.
Industry Background
This agreement follows a protracted row between the drug companies and the UK government over drug pricing and regulatory access.
This friction were heightened by claims that American customers were paying a premium for the same drugs than consumers in the other developed nations.
Recently, several major manufacturing plans in the UK have been halted or abandoned, while multi-billion-dollar investments have been pledged toward US facilities.
One official stated that the NHS must increase expenditure on medicines, noting that its spending on drugs had declined as a percentage of its overall budget over the last ten years.
